Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology

 Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology

Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology

Shots:

  • Avidity to receive $20M upfront, $15M equity investment, $405M as development, regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop and commercialize the products to be developed in immunology and other indications
  • The companies will develop & commercialize RNA-based therapies with the combination of tissue selectivity of mAb with oligonucleotide-based candidates utilizing Avidity’s AOC technology
  • Avidity’s antibody oligonucleotide conjugate (AOC) technology combines the cellular and tissue selectivity of mAbs with oligonucleotide-based therapies, modulating RNA in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells

Click here to read full press release/ article | Ref: Eli Lilly | Image: Chemical Industry Digest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post